- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02251769
Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir
September 25, 2014 updated by: Boehringer Ingelheim
A Single-centre Open-label Study in Healthy Adult Volunteers to Determine the Effects of Single-dose and Steady-state TPV/r (500 mg/200 mg) on the Steady-state Pharmacokinetics of Clarithromycin (BIAXIN®) 500 mg Bid and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir
To determine the effects of single-dose and steady-state Tipranavir/Ritonavir (TPV/r) at 500 mg/200 mg bid on the steady-state pharmacokinetics of clarithromycin and to determine the effects of a standard high-fat test meal on the steady-state pharmacokinetics of tipranavir.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects between 18 and 60 years of age inclusive
- A Body Mass Index (BMI) between 18 and 29 kg/m2
- Signed informed consent prior to trial participation
- Ability to swallow multiple capsules without difficulty
- Ability to ingest a standard high-fat test meal
- Acceptable laboratory values that indicated adequate baseline organ function were required at the time of screening. Laboratory values were considered to be acceptable if severity was less than or equal to Grade 1, based on the AIDS Clinical Trials Group (ACTG) Grading Scale
- Acceptable medical history, physical examination and 12-lead ECG were required prior to entering the treatment phase of the study
- Willingness to abstain from alcohol for 48 hours prior to study Day 0 and abstain from alcohol for the duration of the study. In addition, ingestion of red wine is not allowed within 5 days prior to Day 0 (Visit 2)
- Willingness to abstain from grapefruit or grapefruit juice or products containing grapefruit juice starting 10 days prior to any administration of study drug up until the end of the study
- Willingness to abstain from ingestion of Seville oranges, garlic supplements, St. John's Wort, or Milk Thistle, within 5 days of treatment and for the duration of the study
- Willingness to abstain from methylxanthine-containing drinks or foods (coffee, tea, cola, energy drinks, chocolate, etc.) within 48 hours of each pharmacokinetic sampling day and until after the last sample from each of the intensive sampling days was collected
- Willingness to abstain from over the counter herbal medications for the duration of the study
- Willingness to abstain from vigorous physical exercise during intensive pharmacokinetic days
- Reasonable probability for completion of the study
- Non-smokers for at least 3 months prior to Day 0
Exclusion Criteria:
Female subjects who are of reproductive potential and who:
- Have positive serum β-hCG at Visit 1, or on Day 0
- Are not using a barrier contraceptive method for at least 3 months prior to Visit 2 (Day 0)
- Are not willing to use a reliable method of barrier contraception (such as diaphragm or condoms), during the trial and for 30 days after trial completion/termination
- Are breast-feeding
- Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to study initiation and for the duration of the study
- Use of hormone replacement therapy within 1 month prior to study initiation and for the duration of the study
- Participation in another trial with an investigational medicine within 60 days prior to Day 0 (Visit 2)
- Use of any prohibited medication listed in the protocol within 30 days prior to Day 0 (Visit 2)
- Administration of antibiotics within 10 days prior to Day 0 (Visit 2) or during the trial
- History of acute illness within 60 days of trial initiation. Subjects are excluded for these disorders greater than 60 days if, in the opinion of the investigator, the subject does not qualify as a healthy volunteer
- Serological evidence of hepatitis B (HBV) or hepatitis C (HCV)
- Serological evidence of exposure to HIV
- Recent history of alcohol or substance abuse (within 6 months of study period)
- Blood or plasma donations within 30 days prior to Day 0 (Visit 2) or during the trial
- Subjects with a seated systolic blood pressure either <100 mm Hg or >150 mm Hg
- Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering tipranavir (TPV), ritonavir (RTV) or clarithromycin (CLR) to the subject
- Subjects who have taken, within 7 days prior to Day 0 (Visit 2), any over-the-counter or prescription drugs that, in the opinion of the investigator in consultation with the BI clinical monitor, might interfere with either the absorption, distribution or metabolism of the test substances
- Known hypersensitivity to TPV, RTV, sulfonamides, or CLR
- Lactose intolerance or intolerance to high-fat foods
- Allergies or intolerance to foods such as soybean, wheat, milk, eggs or gluten
- Inability to adhere to requirements of the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequential administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under plasma concentration time curve from 0-12 hours (AUC0-12h)
Time Frame: up to 12 hours
|
up to 12 hours
|
Maximum plasma concentration (Cmax)
Time Frame: up to 12 hours
|
up to 12 hours
|
Plasma trough concentration (Cp12h)
Time Frame: up to 12 hours
|
up to 12 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Oral clearance (CL/F)
Time Frame: up to 12 hours
|
up to 12 hours
|
Volume of distribution (V)
Time Frame: up to 12 hours
|
up to 12 hours
|
Apparent terminal half life (t1/2)
Time Frame: up to 12 hours
|
up to 12 hours
|
Time of maximum concentration (Tmax)
Time Frame: up to 12 hours
|
up to 12 hours
|
Mean Residency Time (MRT)
Time Frame: up to 12 hours
|
up to 12 hours
|
Number of patients with adverse events
Time Frame: up to day 13
|
up to day 13
|
Number of patients with clinically significant laboratory findings
Time Frame: up to day 13
|
up to day 13
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2003
Primary Completion (Actual)
September 1, 2003
Study Registration Dates
First Submitted
September 25, 2014
First Submitted That Met QC Criteria
September 25, 2014
First Posted (Estimate)
September 29, 2014
Study Record Updates
Last Update Posted (Estimate)
September 29, 2014
Last Update Submitted That Met QC Criteria
September 25, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Protein Synthesis Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
- Tipranavir
- Clarithromycin
Other Study ID Numbers
- 1182.11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Tipranavir
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedHIV InfectionsUnited States, Puerto Rico
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimTerminated
-
Boehringer IngelheimApproved for marketingHIV InfectionsBelgium, Brazil, Canada, Denmark, El Salvador, Greece, Italy, Portugal, Spain
-
Boehringer IngelheimCompletedHIV InfectionsUnited States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Italy, Mexico, Netherlands, Portugal, Spain, Switzerland, United Kingdom
-
Boehringer IngelheimApproved for marketingHIV InfectionsUnited States, Australia, Belgium, Denmark, France, Greece, Ireland, Italy, Portugal, South Africa, Switzerland, United Kingdom
-
Boehringer IngelheimWithdrawn
-
Boehringer IngelheimTerminatedHIV InfectionsUnited States, Argentina, Brazil, France, Germany, Italy, Spain